id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-316616-j82q99in	Su, Yen-Bo	Cardiovascular manifestation and treatment in COVID-19	2020-05-19		.txt	text/plain	4445	243	36	The novel coronavirus disease 2019 (COVID-19), with first presentation of atypical pneumonia, has spread rapidly from Wuhan, China, on December 12, 2019 to over 200 countries, caused 2 310 572 infected individuals and 158 691 mortalities, updated on April 19, 2020. 33, 41 In a small singlearm study of patients with confirmed COVID-19, treatment with hydroxychloroquine was associated with a significant difference in clearing of viral nasopharyngeal carriage of SARS-CoV2 within 3 to 6 days when compared with untreated controls. ACE2 levels are increased following treatment with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which yield the concerns that using these medications might increase the severity of COVID-19, especially in patients with existing cardiovascular diseases. Patients with comorbidities including hypertension, cardiovascular diseases, and diabetes tend to have higher risk for having severe COVID-19 which leads to acute respiratory distress syndrome (ARDS) and mortality. Risk factors associated with acute respiratory distress syndrome and death in patients With coronavirus disease 2019 pneumonia in Wuhan, China	./cache/cord-316616-j82q99in.txt	./txt/cord-316616-j82q99in.txt